After a stage 3b rectal cancer diagnosis, one patient endured radiation, chemotherapy, surgery, and complications, relying on resilience, advocacy and support.

The phase 3 NRG Oncology GU005 trial tested SBRT vs MH-IMRT radiation for intermediate-risk prostate cancer for disease control and quality of life.

The co-primary endpoints were safety and efficacy: efficacy defined as ≥25% reduction in rectal rV70 in >75% of balloon ...

For patients with intermediate-risk localized prostate cancer, stereotactic body radiation therapy (SBRT) yields favorable bowel health-related quality of life (HRQOL).

Results of the NRG Oncology NRG-GU005 clinical study comparing stereotactic body radiation therapy (SBRT) to moderately hypofractionated intensity-modulated radiation therapy (MH-IMRT) for patients ...

Dr. Yu began by highlighting that moderately hypofractionated IMRT (MH-IMRT) has been the standard of care for prostate cancer since RTOG 0415 and other landmark studies. 1 At the time this trial was ...

Among patients with locally advanced rectal cancer, concurrent chemoradiotherapy did not significantly increase second pelvic malignancies compared to chemotherapy alone, but it did raise the risk for ...

A new phase III clinical trial finds that intensity-modulated radiation therapy (IMRT) and proton beam therapy resulted in ...